Feasibility of PRISM
Primary
· 8 months 4 weeks
Feasibility was defined as 70% of participants completing all sessions and pre/post surveys.
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 33 | |
| PRISM Intervention | 10 |
Last reviewed · How we verify
NCT06133348: PRISM
Promoting Resilience in Women With Breast Cancer
Completed
NA
Results posted
Last updated 10 November 2025
What this trial tests
NA trial testing Promoting Resilience in Stress Management Intervention in Breast Cancer in 43 participants. Completed in 23 October 2024.
Timeline
24 January 2024
Primary endpoint
23 October 2024
23 October 2024
23 October 2024
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 43 |
| Start date | 24 January 2024 |
| Primary completion | 23 October 2024 |
| Estimated completion | 23 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Promoting Resilience in Stress Management Intervention
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
University of Alabama at Birmingham
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Acceptable, Appropriate, and Feasible
Secondary
· post-PRISM (ranged from 1 to 7 months after baseline)
Acceptability, appropriateness, and feasibility of the intervention were measured using the Acceptability of Intervention Measure (AIM; scored 1-5), Intervention Appropriateness Measure (IAM; scored 1-5), and Feasibility of Intervention Measure (FIM; scored 1-5). Higher scores indicated better outcomes for each validated survey tool. If means are greater than 4, then the study is considered acceptable, appropriate, and/or feasible.
Acceptability of Intervention Measure (AIM)
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 4.5 | ± 0.7 |
Intervention Appropriateness Measure (IAM)
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 4.5 | ± 0.8 |
Feasibility of Intervention Measure (FIM)
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 4.6 | ± 0.5 |
Resilience
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Connor-Davidson Resilience scale (CD-RISC; scored 0-40, higher scores indicate greater resilience)
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 28.5 | ± 7.0 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 31.8 | ± 5.6 |
Overall Post-Traumatic Growth Inventory
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Post-Traumatic Growth Inventory (PTGI; scored 0-105 with factor subscales ranging from 0-10 to 0-35; higher scores indicate more positive transformation). Sub-scores are summed together to receive the overall score.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 57.4 | ± 28.7 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 67.8 | ± 28.6 |
Post-Traumatic Growth Inventory: Personal Strength Sub-scale
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Post-Traumatic Growth Inventory (PTGI; scored 0-105; higher scores indicate more positive transformation). The Post-Traumatic Growth Inventory Personal Strength sub-scale is scored from 0-20 with higher scores indicating increased resilience, self-reliance, confidence, humility, etc.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 10.9 | ± 6.0 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 13.2 | ± 6.1 |
Post-Traumatic Growth Inventory: New Possibilities Sub-scale
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Post-Traumatic Growth Inventory (PTGI; scored 0-105; higher scores indicate more positive transformation). The Post-Traumatic Growth Inventory New Possibilities sub-scale is scored from 0-25 with higher scores indicating an increase in new interests, perspectives, more adaptability and openness to new opportunities.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 11 | ± 6.9 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 14.5 | ± 7.1 |
Post-Traumatic Growth Inventory: Improved Relationships Sub-scale
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Post-Traumatic Growth Inventory (PTGI; scored 0-105; higher scores indicate more positive transformation). The Post-Traumatic Growth Inventory Improved Relationship sub-scale is scored from 0-35 with higher scores indicating an increased sense of belonging, emotional vulnerability, empathy, more supportive, and have an increased ability to form stronger bonds with others.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 20 | ± 9.9 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 22.9 | ± 9.2 |
Post-Traumatic Growth Inventory: Spiritual Growth Sub-scale
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Post-Traumatic Growth Inventory (PTGI; scored 0-105; higher scores indicate more positive transformation). The Post-Traumatic Growth Inventory Spiritual Growth sub-scale is scored from 0-10 with higher scores indicating deeper and more meaningful beliefs, life philosophies and faith, more awareness, and a clearer purpose in life.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 6 | ± 3.7 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 6.7 | ± 3.7 |
Post-Traumatic Growth Inventory: Appreciation for Life Sub-scale
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Post-Traumatic Growth Inventory (PTGI; scored 0-105; higher scores indicate more positive transformation). The Post-Traumatic Growth Inventory Appreciation for Life sub-scale is scored from 0-15 with higher scores indicating increased gratitude, appreciation for the positive things in life, and clearer sense of priorities.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 9.5 | ± 4.8 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 10.5 | ± 4.7 |
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being tool (FACIT-Sp; scored 0-48 with each factor scored 0-16, higher scores indicate greater spiritual well-being). The overall score is a summation of each sub-score.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 37.1 | ± 8.2 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 40.5 | ± 5.4 |
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being: Meaning Sub-score
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being tool (FACIT-Sp; scored 0-48 with higher scores indicate greater spiritual well-being). The Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Meaning sub-scale is scored from 0-16 with one question reverse coded. Item scores for the sub-scale are summed, multiplied by 4, and divided by the number of items answered by the participant. A higher score indicates a greater sense of a meaningful life.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 13.2 | ± 3 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 14.5 | ± 1.7 |
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being: Peace Sub-score
Secondary
· pre-PRISM (Baseline) and post-PRISM (ranged from 1 to 7 months after baseline)
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being tool (FACIT-Sp; scored 0-48 with higher scores indicate greater spiritual well-being). The Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Peace sub-scale is scored from 0-16 with one question reverse coded. Item scores for the sub-scale are summed, multiplied by 4, and divided by the number of items answered by the participant. A higher score indicates a greater sense of inner peace or harmony.
pre-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 11 | ± 3.4 |
post-PRISM
| Group | Value | 95% CI |
|---|---|---|
| PRISM Intervention | 12.5 | ± 2.6 |
Sponsor's own description
The PRISM (Promoting Resilience in Stress Management) intervention is an evidence-based program that builds resilience. This program was developed in adolescent and young adult oncology and utilizes centrally administered skills-based coaching to bolster positive psychological tools known as resilience resources. These resources include stress management, goal-setting, and positive reframing. Previous studies using this intervention have found PRISM to be successfully administered remotely and it has improved resilience, psychological distress, hope, and quality of life. Among adult caregivers, PRISM has shown to improve resilience, self-efficacy, and engagement with medical care. While PRISM successfully targets distress and associated downstream consequences known to be experienced by breast cancer survivors, it has not been utilized in adults with cancer or in marginalized communities. Adapting this intervention to this context will require the testing of the intervention and, importantly, tailoring to meet the needs of women with breast cancer, particularly those of marginalized populations who may uniquely benefit from this intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06133348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06133348 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 10 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06133348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing